Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Sep 9:3:16.
doi: 10.1186/1471-2288-3-16. Epub 2003 Sep 9.

A perfect correlate does not a surrogate make

Affiliations

A perfect correlate does not a surrogate make

Stuart G Baker et al. BMC Med Res Methodol. .

Abstract

Background: There is common belief among some medical researchers that if a potential surrogate endpoint is highly correlated with a true endpoint, then a positive (or negative) difference in potential surrogate endpoints between randomization groups would imply a positive (or negative) difference in unobserved true endpoints between randomization groups. We investigate this belief when the potential surrogate and unobserved true endpoints are perfectly correlated within each randomization group.

Methods: We use a graphical approach. The vertical axis is the unobserved true endpoint and the horizontal axis is the potential surrogate endpoint. Perfect correlation within each randomization group implies that, for each randomization group, potential surrogate and true endpoints are related by a straight line. In this scenario the investigator does not know the slopes or intercepts. We consider a plausible example where the slope of the line is higher for the experimental group than for the control group.

Results: In our example with unknown lines, a decrease in mean potential surrogate endpoints from control to experimental groups corresponds to an increase in mean true endpoint from control to experimental groups. Thus the potential surrogate endpoints give the wrong inference. Similar results hold for binary potential surrogate and true outcomes (although the notion of correlation does not apply). The potential surrogate endpoint would give the correct inference if either (i) the unknown lines for the two group coincided, which means that the distribution of true endpoint conditional on potential surrogate endpoint does not depend on treatment group, which is called the Prentice Criterion or (ii) if one could accurately predict the lines based on data from prior studies.

Conclusion: Perfect correlation between potential surrogate and unobserved true outcomes within randomized groups does not guarantee correct inference based on a potential surrogate endpoint. Even in early phase trials, investigators should not base conclusions on potential surrogate endpoints in which the only validation is high correlation with the true endpoint within a group.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Graphical depiction of incorrect inference based on surrogage endpoints. The graph shows perfectly correlated results (namely a straight line) for the relationship between surrogate and true outcomes for a control group C and experimental group E. The mean surrogate outcome in the E group formula image is smaller than the mean surrogate outcome in the C group formula image. However the mean true outcome in the E group formula image is larger than the mean true outcome in the C group, formula image, yielding the opposite conclusion for the effect of experimental intervention.

Similar articles

Cited by

References

    1. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine. 1996;125:605–613. - PubMed
    1. Biomarkers Definition Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001;69:89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. Journal of the American Medical Association. 2002;288:2321–333. doi: 10.1001/jama.288.3.321. - DOI - PubMed
    1. Sandier RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New England Journal of Medicine. 2003;348:883–890. doi: 10.1056/NEJMoa021633. - DOI - PubMed
    1. Baron JA, Cole BF, Sandier RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. New England Journal of Medicine. 2003;348:891–899. doi: 10.1056/NEJMoa021735. - DOI - PubMed

MeSH terms

LinkOut - more resources